Loading…
Employees: 1,545
Size Edding Genor (6998.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $408M, the 817th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$1.59 on 6 Nov 2026.
Performance Over six months the shares fell 45.2%, against -18.2% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 1,417.7% over the last twelve months (peer median +12.9%); the operating margin is 26.2% (peer median -9.8%).
Valuation It trades at 0.9× enterprise value to sales against a peer median of 5.3× (2nd cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -16% a year for seven years (Req g). Recent delivered growth is +197%, so the hurdle is -213 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.8 points above its cost of capital (8.6% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$3.68B | HK$2.70B | HK$2.76B | HK$0 | HK$18.5M |
| Revenue growth | — | -2% | — | -100% | — |
| Gross profit | HK$2.59B | HK$1.76B | HK$1.78B | -HK$85.0M | -HK$45.0M |
| EBITDA | n/a | HK$954M | HK$924M | -HK$687M | -HK$852M |
| Net income | HK$421M | HK$433M | HK$421M | -HK$745M | -HK$849M |
| Free cash flow | HK$616M | HK$236M | HK$688M | -HK$471M | -HK$686M |
| Capital expenditure | HK$61.4M | HK$51.7M | HK$218M | HK$1.14M | HK$15.1M |
| Total debt | n/a | HK$1.66B | HK$2.16B | HK$7.88M | HK$32.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6998.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.5% | -8.5% | 7th highest of 21 |
| 6-month return | -45.2% | -18.2% | 2nd lowest of 21 |
| Distance from 52-week high | -59.2% | -42.6% | 4th lowest of 21 |
| Revenue growth (TTM) | +1,417.7% | +12.9% | highest of 18 |
| Operating margin | 26.2% | -9.8% | 4th highest of 18 |
| EV / Sales | 0.9× | 5.3× | 2nd cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -15.8% | 4.9% | 2nd least demanding of 7 |
| Growth delivered (Del g) | +197.3% | +37.6% | 2nd highest of 6 |
| Hurdle (Req g minus delivered) | -213.2 pp | -2.4 pp | 2nd least demanding of 6 |
| ROIC minus cost of capital | +7.8 pp | -9.0 pp | 5th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Edding Genor 6998.HK | Hong Kong | $408M | -45% | +1,418% | 26% | 0.9× | -15.8% | +197.3% |
| Prothena PRTA | United States | $409M | -26% | +427% | -110% | 2.4× | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $410M | -19% | +3% | 0% | 1.6× | 43.0% | +8.9% |
| Altimmune ALT | United States | $405M | -33% | +55% | -320,726% | 3,686.9× | n/a | n/a |
| CorMedix CRMD | United States | $415M | -33% | +280% | 47% | 0.7× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $415M | -17% | +230% | 56% | 2.5× | -20.2% | n/a |
| Kamada KMDA | United States | $417M | -15% | +11% | 14% | 1.8× | 4.1% | +6.5% |
| Arvinas ARVN | United States | $420M | -37% | -12% | -10% | n/a | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | 5.4× | n/a | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | 28.4× | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | n/a | n/a | n/a |
| Polynovo PNV.AX | Australia | $426M | -12% | +13% | 5% | 4.2× | 53.3% | +37.6% |
| EirGenix 6589.TW | Taiwan | $427M | +2% | +27% | -71% | 10.7× | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $427M | -7% | +6% | -10% | 6.4× | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | 244.5× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | 2.7× | n/a | n/a |
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | 5.3× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $439M | +9% | +13% | 47% | 12.7× | 5.8% | +70.5% |